在阴茎癌的预后标记和试验
Naufal Naushad1, Abdalla A Deb2, Ayman A Agag3
1Department of Urology, Christie NHS Foundation Trust, Manchester, UK.
Urology research & practice
|October 25, 2023
概括
新的瘤生物标志物为阴茎癌提供了个性化治疗. 然而,相互矛盾的研究需要在临床应用前进行进一步的研究,以治疗阴茎状细胞癌.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 癌症生物标志物 癌症生物标志物
背景情况:
- 阴茎状细胞癌 (PSCC) 管理正在随着新瘤生物标志物的鉴定而发展.
- 现有的PSCC生物标志物研究显示出有希望的结果,但存在不一致的发现,需要进一步验证.
- 在定制PSCC治疗中生物标志物的临床实用性仍在研究中.
研究的目的:
- 审查阴茎癌的突出的和新兴的生物标志物.
- 总结目前专注于阴茎癌患者管理的临床试验.
- 提供一个概述的潜力,以生物标志物驱动的个性化药物在PSCC.
主要方法:
- 这项研究采用了叙事审查方法.
- 文献搜索侧重于常见的和最近研究的阴茎癌生物标志物.
- 包括注册的阴茎癌治疗临床试验的摘要.
主要成果:
- 几种生物标志物显示出PSCC诊断和预后的潜力.
- 对于一些生物标志物而言,存在矛盾的结果,这突显了需要强有力的验证的需要.
- 一些临床试验正在积极研究阴茎癌的新疗法策略.
结论:
- 生物标志物发现对于推进阴茎癌个性化治疗至关重要.
- 进一步严格的研究是必要的,以解决当前的争议,并建立生物标志物的可靠性.
- 将验证的生物标志物纳入临床实践可以显著改善PSCC患者的治疗结果.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.1K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancer Survival Analysis
357
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
357
